Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C9E5 | ISIN: US00444A1016 | Ticker-Symbol:
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ACCUSTEM SCIENCES INC Chart 1 Jahr
5-Tage-Chart
ACCUSTEM SCIENCES INC 5-Tage-Chart

Aktuelle News zur ACCUSTEM SCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
20.05.Accustem Sciences Inc. - 10-Q, Quarterly Report1
28.04.AccuStem Sciences, Inc. and EmeritusDX Announce Partnership to Commercialize MSC Test for Lung Cancer Screening286LONDON and PHOENIX, Ariz., April 28, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk...
► Artikel lesen
21.04.AccuStem Sciences reports share purchase by Chairman3
21.04.AccuStem Sciences, Inc. Announces Chairman Purchase of Shares176LONDON and PHOENIX, Ariz., April 21, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced...
► Artikel lesen
16.04.AccuStem Sciences, Inc. Signs Agreement to Access Blood Samples from Lung Cancer Screening Trial to Expedite MSC Commercialization Plan265LONDON and PHOENIX, April 16, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer...
► Artikel lesen
ACCUSTEM SCIENCES Aktie jetzt für 0€ handeln
10.04.AccuStem Sciences, Inc. Announces Chairman Purchase of Shares217LONDON and PHOENIX, April 10, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced...
► Artikel lesen
08.04.AccuStem Sciences, Inc. Announces Chairman Purchase of Shares1
04.04.AccuStem Sciences, Inc.: AccuStem Sciences to Offer its MSC Blood Test to Lung Cancer Screening Programs in the United States326LONDON and PHOENIX, April 04, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer...
► Artikel lesen
03.04.Accustem Sciences Inc. - 10-K, Annual Report2
18.03.AccuStem Sciences, Inc. Announces Acquisition of Proprietary MSC Lung Cancer Screening Test236AccuStem pursuing strategic commercialization plan intending to launch the MSC test in the US in 2026 LONDON and PHOENIX, Ariz., March 18, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:...
► Artikel lesen
03.01.AccuStem Sciences announces chairman purchase of shares6
03.01.AccuStem Sciences, Inc. Announces Chairman Purchase of Shares311LONDON and PHOENIX, Jan. 03, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced...
► Artikel lesen
30.12.24Accustem Sciences Inc. - 8-K, Current Report1
13 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1